Literature DB >> 17008302

Thrombin activatable fibrinolysis inhibitor (TAFI)--how does thrombin regulate fibrinolysis?

Bonno N Bouma1, Laurent O Mosnier.   

Abstract

The thrombin-catalysed conversion of plasma fibrinogen into fibrin and the development of an insoluble fibrin clot are the final steps of the coagulation cascade during haemostasis. A delicate balance between coagulation and fibrinolysis determines the stability of the fibrin clot. Thrombin plays a central role in this process, it not only forms the clot but it is also involved in stabilizing the clot by activating thrombin activatable fibrinolysis inhibitor (TAFI). Activated TAFI protects the fibrin clot against lysis. Here we will discuss the mechanisms for regulation of fibrinolysis by thrombin. The role of the coagulation system for the generation of thrombin and for the activation of TAFI implies that defects in thrombin generation will directly affect the protection of clots against lysis. Thus, defects in activation of TAFI might contribute to the severity of bleeding disorders. Vice versa an increased activation of TAFI due to an increased rate of thrombin generation might lead to thrombotic disorders. Specific inhibitors of activated TAFI or inhibitors that interfere with the generation of thrombin might provide novel therapeutic strategies for thrombolytic therapy. Besides having a role in the regulation of fibrinolysis, TAFI may also have an important function in the regulation of inflammation, wound healing and blood pressure.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17008302     DOI: 10.1080/07853890600852898

Source DB:  PubMed          Journal:  Ann Med        ISSN: 0785-3890            Impact factor:   4.709


  23 in total

1.  Thrombin activatable fibrinolysis inhibitor and thrombin-antithrombin-III-complex levels in patients with gastric cancer.

Authors:  Evren Fidan; Halil Kavgaci; Asim Orem; Mustafa Yilmaz; Bulent Yildiz; Sami Fidan; Buket Akcan; Feyyaz Ozdemir; Fazil Aydin
Journal:  Tumour Biol       Date:  2012-04-27

2.  Deficiency of superoxide dismutase impairs protein C activation and enhances susceptibility to experimental thrombosis.

Authors:  Sanjana Dayal; Sean X Gu; Ryan D Hutchins; Katina M Wilson; Yi Wang; Xiaoyun Fu; Steven R Lentz
Journal:  Arterioscler Thromb Vasc Biol       Date:  2015-06-11       Impact factor: 8.311

Review 3.  Arterial thrombus formation in cardiovascular disease.

Authors:  Giuseppe Lippi; Massimo Franchini; Giovanni Targher
Journal:  Nat Rev Cardiol       Date:  2011-07-05       Impact factor: 32.419

4.  [Analysis of prophylactic effect of extended-duration anticoagulant drugs in elderly patients undergoing hip fracture].

Authors:  W Zhang; P X Zhang
Journal:  Beijing Da Xue Xue Bao Yi Xue Ban       Date:  2019-06-18

5.  PAR-1 antagonist vorapaxar favorably improves global thrombotic status in patients with coronary disease.

Authors:  G Rosser; P Tricoci; D Morrow; C Christopoulos; M N Niespialowska-Steuden; R Kozarski; R Wilcox; D A Gorog
Journal:  J Thromb Thrombolysis       Date:  2014-11       Impact factor: 2.300

6.  Plasmin generation and fibrinolysis in pediatric patients undergoing cardiopulmonary bypass surgery.

Authors:  Vera Ignjatovic; Aparajith Chandramouli; Jenny Than; Robyn Summerhayes; Fiona Newall; Steve Horton; Andrew Cochrane; Paul Monagle
Journal:  Pediatr Cardiol       Date:  2011-10-02       Impact factor: 1.655

7.  Substrate specificity of human carboxypeptidase A6.

Authors:  Peter J Lyons; Lloyd D Fricker
Journal:  J Biol Chem       Date:  2010-09-20       Impact factor: 5.157

8.  Viscoelastic measurements of platelet function, not fibrinogen function, predicts sensitivity to tissue-type plasminogen activator in trauma patients.

Authors:  H B Moore; E E Moore; M P Chapman; E Gonzalez; A L Slaughter; A P Morton; A D'Alessandro; K C Hansen; A Sauaia; A Banerjee; C C Silliman
Journal:  J Thromb Haemost       Date:  2015-09-22       Impact factor: 5.824

9.  Aqueous two-phase deposition and fibrinolysis of fibroblast-laden fibrin micro-scaffolds.

Authors:  Stephen Robinson; Jonathan Chang; Eric Parigoris; Louise Hecker; Shuichi Takayama
Journal:  Biofabrication       Date:  2021-04-07       Impact factor: 9.954

10.  Operative debridement of pressure ulcers.

Authors:  Jessica Schiffman; Michael S Golinko; Alan Yan; Anna Flattau; Marjana Tomic-Canic; Harold Brem
Journal:  World J Surg       Date:  2009-07       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.